Cargando…

Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

BACKGROUND: Liver Transplantation (LT) is treatment of choice for patients with hepatocellular carcinoma (HCC) within MILAN Criteria. Tumour progression and subsequent dropout from waiting list have significant impact on the survival. Transarterial chemoembolization (TACE) controls tumour growth in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann, Katrin, Ganten, Tom, Gotthardtp, Daniel, Radeleff, Boris, Settmacher, Utz, Kollmar, Otto, Nadalin, Silvio, Karapanagiotou-Schenkel, Irini, von Kalle, Christof, Jäger, Dirk, Büchler, Markus W, Schemmer, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449604/ https://www.ncbi.nlm.nih.gov/pubmed/25957784 http://dx.doi.org/10.1186/s12885-015-1373-z

Ejemplares similares

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib(® )versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]
por: Hoffmann, K, et al.
Publicado: (2008)

Living donor liver transplantation with two-stage hepatectomy for patients with isolated, irresectable colorectal liver—the LIVER-T(W)O-HEAL study
por: Rauchfuß, Falk, et al.
Publicado: (2019)

An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2(nd )or higher line chemotherapy regarding clinical benefit - PANUSCO
por: Märten, Angela, et al.
Publicado: (2009)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation
por: Minoux, Kate, et al.
Publicado: (2022)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
por: Seidensticker, Max, et al.
Publicado: (2023)

GHR knockdown enhances the sensitivity of HCC cells to sorafenib
por: Gao, Shuang, et al.
Publicado: (2020)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
por: He, Xi, et al.
Publicado: (2021)

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
por: Chow, Ariel Ka-Man, et al.
Publicado: (2013)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
por: Shrestha, Ritu, et al.
Publicado: (2021)

Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study
por: Nikoghosyan, Anna V, et al.
Publicado: (2010)

Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC
por: Hajighasemlou, Saieh, et al.
Publicado: (2020)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
por: Fornari, Francesca, et al.
Publicado: (2021)

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
por: Pinyol, Roser, et al.
Publicado: (2019)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
por: Lai, Hong-Yue, et al.
Publicado: (2021)

Validation of a Lab-on-Chip Assay for Measuring Sorafenib Effectiveness on HCC Cell Proliferation
por: Piccinno, Emanuele, et al.
Publicado: (2021)

Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)

Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients
por: Feng, Yu-Min, et al.
Publicado: (2015)

LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription
por: Lin, Zhongjie, et al.
Publicado: (2020)

A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC
por: Liu, Xiang, et al.
Publicado: (2022)

Anti-angiogenic effect of the combination of low-dose sorafenib and EGCG in HCC-induced Wistar rats
por: Irawan, Andry, et al.
Publicado: (2022)

Acute and Chronic Infections of the Gastrointestinal Tract
por: Stallmach, Andreas, et al.
Publicado: (2014)

Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
por: Qu, Zhen, et al.
Publicado: (2016)

Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis
por: Gu, Wang, et al.
Publicado: (2020)

Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical management
por: Lin, Yan, et al.
Publicado: (2022)

Accuracy of Estimation of Graft Size for Living-Related Liver Transplantation: First Results of a Semi-Automated Interactive Software for CT-Volumetry
por: Mokry, Theresa, et al.
Publicado: (2014)

Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial
por: Combs, Stephanie E, et al.
Publicado: (2011)

NEO E-vita—NEO era!
por: Jakob, Heinz, et al.
Publicado: (2022)

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
por: Faloppi, Luca, et al.
Publicado: (2014)

A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
por: Xu, Yu-Yin, et al.
Publicado: (2013)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
por: Lee, Jaejun, et al.
Publicado: (2020)

Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC
por: Zhou, Kevin, et al.
Publicado: (2022)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1njpr71fq5ofvfd8r6cedf492g